Introduction
Although recent studies indicate that angiotensin blockade retards the deterioration of renal function in chronic kidney diseases (CKDs), there is still controversy that angiotensin blockade is renoprotective independent of blood pressure control. [1] [2] [3] [4] [5] Many patients with CKDs suffer cardiovascular complications during the early course, and atherosclerotic cardiovascular diseases (CVDs) constitute major cause of death in CKDs. [6] [7] [8] The prevention of atherosclerosis in CKDs should be of great importance. Renal insufficiency itself as well as hypertension could increase cardiovascular events. 6, 7, 9 It is beneficial for the patients with CKD not only to retard the progression of renal dysfunction, but also to prevent the development of CVDs. Peripheral artery disease is prevailing in this patient population. 10, 11 In hypertensive patients, angiotensinconverting enzyme inhibitor (ACEI) has been shown to improve cardiovascular survival. 12 Angiotensin receptor blocker (ARB) improves the prognosis of diabetic as well as hypertensive patients. 2, 13 Angiotensin blockade reduces cardiovascular death in chronic haemodialysis patients. 14 However, it remains to be determined whether angiotensin inhibition improves patient prognosis with CKDs of mild-to-moderate renal dysfunction.
Recent technical progress makes non-invasive measurements of arterial stiffness possible. Pulse wave velocity (PWV) is an index of arterial stiffness that is one of the characters of atherosclerosis, and considered as a surrogate cardiovascular risk factor. [15] [16] [17] [18] [19] [20] PWV correlates to various cardiovascular risk factors such as age, blood pressure, hyperlipidemia, homocysteine and vascular calcification. Angiotensin II could elevate arterial stiffness, by increasing arterial thickness either with atheroma, fibrosis or smooth muscle proliferation. Angiotensin II induces the expression of various oncogenes, the proliferation of vascular smooth muscle cells and the stimulation of synthesis of collagen and other extracellular matrix. 21, 22 In addition, angiotensin II promotes fibroblasts to produce reactive oxygens in vascular beds, participating in atherogenesis. 11, 23 High PWV predicts the presence of coronary artery disease and cardiovascular death. [15] [16] [17] 20 Since PWV can be measured repeatedly in the individual patient, it enables chronological assessment of the magnitude in atherosclerosis. Thus, we used PWV as secondary end point of the present study. Our previous data suggest that combined treatment with angiotensin inhibition and lipid-lowering drugs or vitamin E could improve PWV in patients with endstage renal failure. 18 However, it is not clear whether angiotensin blockade may slow the progression of arterial stiffness in CKDs.
In the present study, we examined the influence of angiotensin inhibition on the prognosis of nondiabetic CKDs. Furthermore, we assessed the effects of angiotensin inhibition on PWV in non-diabetic kidney diseases. To our knowledge, the present findings have provided the first evidence that angiotensin blockade helps keep vascular health in the patients with non-diabetic CKDs of mild-tomoderate renal dysfunction, possibly accounting for that angiotensin inhibition could induce better prognosis for the patients with CKDs.
Methods
In 2002, we listed for the study the patients with non-diabetic CKDs who had started to take antihypertensives within a year, with their acceptance of an informed consent. CKDs were diagnosed by either persistent abnormality in urine analysis, abnormal renal imaging, abnormal renal histology based on biopsy or creatinine clearance (Ccr) less than 60 ml/min. Ccr was calculated using serum creatinine (Scr) with Cockcroft-Gault equation. 24 Randomized controlled prospective study was performed to assess the effects of angiotensin blockade either with an ACEI or with an ARB. The days when patients were enrolled were randomized. Randomization was attained by an envelope method. On one day, patients with angiotensin inhibition were enrolled. On the other day, patients without angiotensin inhibition were enrolled. Initially, 102 patients entered the study. The following patients were not enrolled: patients with severe renal failure including those on dialysis therapy, receiving renal transplantation or Ccr less than 15 ml/min, patients treated with corticosteroid or immunosuppressant, patients with myocardial infarction or stroke including transient ischaemic attack, patients with unstable angina pectoris, patients with valvular heart diseases or persistent arrhythmia, patients with aortic aneurysm or aortic replacement with artificial vessels, patients with heart failure or left ventricular ejection fraction of 40% or less, or with a disorder that in the treating physician's opinion. The doses of antihypertensive drugs had titrated to keep sitting blood pressure of 130/80 mm Hg with the attention to avoid side effects. 25 We also excluded 12 patients of poor compliance. Ten patients expressed their unwillingness to continue the study.
Some of the participating patients had received renal biopsy (Table 1) , and there were 24 patients with immunoglobulin A (IgA) nephropathy, 2 with membranous nephropathy, 10 with mesangial proliferative glomerulonephritis. Medical history and renal imaging study revealed 8 patients with polycystic kidney disease, 1 with unilateral renal agenesis and 18 with benign or malignant nephrosclerosis. Five patients suffered chronic renal injury associated with surgery. Underlying kidney diseases were not well defined for the other 7 patients. Diabetes was ruled out either by medical history or by 75 g oral glucose tolerance test if necessary. Blood pressure was measured between 0900 and 1100 hours using a mercury sphygmomanometer; the first and the fifth Korotkoff's sounds were used to identify systolic and diastolic values respectively. Two measurements were performed with the patient in the sitting position for 5 and 10 min respectively, and the average of the two values was taken as the clinical blood pressure for the purpose efficacy analysis. Patients were followed up for 4 years with regular visits and upward titration of medication to reach a target blood pressure of 130/80 mm Hg. The primary end point of the study was death including renal death, and the secondary end point was arterial stiffness. Patients were followed up until death, Ccr was halved or starting renal replacement therapy (RRT), whichever occurred first (Figure 1 ). Arterial stiffness was repeatedly assessed for 4 years. The trial protocol was approved by the ethics committees and was conducted in accordance with the principles of the Declaration of Helsinki, overseen by an independent data and safety monitoring board. PWV was used as an index of arterial stiffness. 26 At first, heart-ankle (ha)PWV, brachial-ankle (ba)PWV and ankle brachial pressure index (ABI) were simultaneously determined in 2002. A year later (that is in 2003), haPWV, baPWV and ABI were again assessed. Finally, 4 year later (that is in 2006), haPWV, baPWV and ABI were obtained. ABI, haPWV and baPWV were measured using an automated polygraph apparatus (AT-Form PWV/ ABI; Colin, Co., Ltd, Aichi, Japan). This instrument simultaneously records pulse waveform, blood pressure, electrocardiogram and heart sounds, as detailed previously. 17 Each patient was examined in the supine position, with electrocardiogram electrodes placed on both wrists, a microphone for detecting heart sounds placed on the left edge of the sternum and cuffs wrapped on both the brachia and ankles. The cuffs were connected to a plethysmographic sensor that determines volume pulse form, and to an oscillometric pressure sensor that measures blood pressure. The pulse volume waveforms were recorded using a semiconductor pressure sensor (the sample acquisition frequency for PWV was set at 1200 Hz). The best consecutive 10 pulses were analysed with automatic gain analysis and quality adjustment. Only one person (Ms Mami
Analyzed (n=23) Excluded (n=14) due to death, RRT or low ABI Analyzed (n=28) Excluded (n=10) due to death, RRT or low ABI PWV Analysis Figure 1 The flowchart of patients. RRT, Ccr and ABI indicate renal replacement therapy, creatinine clearance and ankle brachial pressure index respectively.
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Dogi from Colin Co., Ltd) performed all measurements of ABI and PWVs, and the coefficients of variations of haPWV and baPWV were less than 5%. The mean value of the phase velocity above 2-2.5 Hz was very close to the wave front velocity. 27 The characteristic points of waveforms were determined automatically according to this phase velocity theory. The components over 5 Hz were stored using a pass filter and the wave front was determined. The distances between sampling points of haPWV and baPWV were calculated automatically according to the height of the subject. The path length from the suprasternal notch to the brachium (L1) was obtained from superficial measurements and was expressed using the following equation: L1 ¼ 0.2195 Â height of the patient (in cm)À2.0734. The path length from the suprasternal notch to the ankle (L2) was obtained from superficial measurements and was expressed using the following equation: L2 ¼ 0.8129 Â height of the patient (in cm) þ 12.328. The time interval between the wave front of the brachial waveform and that of the ankle waveform was defined as the time interval between the brachium and ankle (T1). The time interval between second heart sound and aortic notch in brachial artery was defined as that between heart and brachium (T2). Finally, the following equations were used to obtain PWV: baPWV ¼ (L2ÀL1)/T1, and haPWV ¼ L2/(T1 þ T2) respectively. Thus, haPWV reflected the stiffness of not only elastic, but also muscular artery, and baPWV mainly reflected that of muscular artery. Both haPWV and baPWV were expressed as centimetre (cm)/second (s).
Data were expressed as means7s.e.m. Analysis of variance, Student's t-test with or without Bonferroni correction, Kaplan-Meier test, logistic regression analysis, Fisher's exact test and multiple regression analysis were used. Po0.05 was considered statistically significant. Table 1 summarized patient background. Age, sex ratio, pulse rate (PR), blood pressure, Scr, Ccr, urinary protein, height and weight were similar between the patients with angiotensin inhibition and those without angiotensin inhibition in 2002. Thus, at the baseline, there were no differences between two groups. In this study, we used the following ACEIs; benazepril (2.5-10 mg/day), imidapril (2.5-5 mg/day), temocapil (2-4 mg/day) and trandolapril (0.5-2 mg/day). We also used ARBs: losartan (25-100 mg/day), candesartan (2-8 mg/day) and valsartan (20-80 mg/day). No patient received dual blockade of angiotensin with both ACEI and ARB. Antihypertensives other than angiotensin inhibitors included amlodipine (2.5-10 mg/day), benidipine (2-8 mg/day), cilnidipine (10 mg/day), diltiazem (90 mg/day), long-acting nifedipine (20-80 mg/ day), manidipine (20 mg/day), furosemide (20-40 mg/ day), trichlormethiazide (1-2 mg/day), atenolol (25-100 mg/day), arotinolol (10-20 mg/day), carvedilol (5-20 mg/day), guanabenz (2 mg/day) and doxazosin (1-4 mg/day). Many patients took multiple antihypertensives to achieve blood pressure of 130/80 mm Hg. Averaged numbers of antihypertensive drugs were 2.670.2 in both groups. Statins (pravastation 10-20 mg/day, simvastatin 5-10 mg/day and atrovastatin 10 mg/day) were prescribed for 44 and 46% of patients with and without angiotensin inhibition. As shown in Figure 1 , five patients dropped out of the study. From control group, three patients were dropped out. One patient moved. The other patient needed to add an ARB to obtain adequate blood pressure control. Another patient claimed to get out of the study. Two patients dropped from angiotensin inhibition group, because they moved. Kaplan-Meier analysis was performed on 37 controls and 38 patients with angiotensin inhibition.
Results

Patient background
Prognosis
One patient passed away in 4 years among 38 patients under angiotensin inhibition due to stroke, Angiotensin, PWV and prognosis T Mimura et al whereas 4 patients among 37 patients died without angiotensin inhibition (Figure 1 ). Causes of death of these four patients were myocardial infarction, stroke (two cases) and sepsis from infection on peripheral artery disease. In addition, two patients needed RRT during 4 years in patients with angiotensin inhibition, whereas six patients without angiotensin inhibition started dialysis. While angiotensin inhibition tended to decrease death or the requirement of dialysis in non-diabetic CKDs of mild-to-moderate renal dysfunction, each of them failed to attain statistical significance if examined respectively (P ¼ 0.14 and 0.11). Of importance, angiotensin inhibition was superior to conventional antihypertensives, regarding composite end point of death and renal death (Po0.05, Figure 2 ). In addition, logistic analysis was performed to assess whether patient background contributed to the primary end point. As shown in Table 3 , angiotensin inhibition was selected as a significant negative contributor to primary end point. Previous studies indicated that angiotensin inhibition improved renal outcome in CKDs. [1] [2] [3] [4] In the present study, one patient passed away in angiotensin inhibition group, and four died in the group without angiotensin inhibition (Figure 1) . Thus, renal prognosis was assessed in 33 controls and 37 patients with angiotensin inhibition. While Ccr was halved in four patients without angiotensin inhibition, Ccr was halved in a single patient under angiotensin inhibition. Consistent with the previous study, 1 angiotensin inhibition lessened unfavourable renal events (RRT and halved Ccr) in non-diabetic CKDs (8 vs 30%, Po0.05) when blood pressure was well controlled (Figure 3 ).
Arterial stiffness
First, a cross-sectional analysis was performed on the data of PWV measured in 2002. Table 4 illustrated the relationship of haPWV to patient background. There were positive correlations of haPWV to age, proteinuria, systolic blood pressure (SBP) and heart rate (HR). Males were prone to show faster haPWV. Table 5 depicted correlations of baPWV with patient background. There was no gender difference in baPWV, but baPWV positively related to age, SBP and HR.
As described in Figure 1 , the data from 11 patients whose ABI fell under 1.0 were excluded from the final analysis on PWV, because arterial stenosis falsely reduces PWV. 18, 26 As depicted above, five baPWV, brachial-ankle pulse wave velocity; BP, blood pressure; Ccr, creatinine clearance; haPWV, heart-ankle pulse wave velocity; OR, odds ratio; PR, pulse rate; UP, urinary protein.
Angiotensin, PWV and prognosis T Mimura et al patients who dropped out of the study were also excluded from PWV analysis. The data from 13 patients who were dead or starting dialysis in 4 years were not included for the analysis of PWV. RRT may give patients additional cardiovascular risk, such as heparin-induced dyslipidemia, oxidative stress from dialyser membrane and glucose overload. 11 Thus, arterial stiffness was compared between 28 patients with angiotensin inhibition and 23 patients without angiotensin inhibition.
In angiotensin inhibition group, both haPWV Ccr, creatinine clearance; DBP, diastolic blood pressure; haPWV, heart-ankle pulse wave velocity; HR, heart rate; SBP, systolic blood pressure; UP, urinary protein. baPWV, brachial-ankle pulse wave velocity; Ccr, creatinine clearance; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; UP, urinary protein. Angiotensin, PWV and prognosis T Mimura et al ageing. 21 We have recently performed an intervention study on more than 2000 hypertensive patients, and found that an ARB has substantially decreased cardiovascular events and that the gain in life span is roughly 10 years. 9 In normotensive animals, ACEI delayed age-related decreases in endothelial function, and also deferred time-dependent increases in intimal and medial thickening. 28, 29 An increase in arterial stiffness is closely related to cardiovascular ageing. 16 , 21 The present data were consistent with those of Blacher et al., 15 and indicated that there were age-related elevations of haPWV and baPWV in CKDs (Tables 4 and 5 ). Wang et al. 30 reported that PWV increased as GFR decreased. Differing onset and duration of heterogeneous kidney diseases among patients could involve the lack of correlation between baseline PWVs and Ccr in the present study. In the present study, angiotensin inhibition arrested progressive increase in PWV. Collectively, to our knowledge, these results provided the first evidence that angiotensin inhibition was exerted as an anti-ageing agent on arterial tree in non-diabetic CKDs.
Carotid-femoral PWV is an index of aortic stiffness. [14] [15] [16] Aorta represents elastic artery, and aortic stiffness relates to cardiovascular prognosis. Blood pressure within a given artery should alter regional PWV of the artery studied. The stiffness of muscular artery as well as that of elastic artery constitutes an important determinant of central pressure, to which terminal organs such as brain, heart and kidney are exposed. 31, 32 The stiffness of muscular artery may influence aortic PWV. Yamashina et al. 17 demonstrated that baPWV measured with this device correlated well with aortic PWV measured by a catheter tip with pressure manometer.
Angiotensin II is involved in the progression of renal diseases via multiple mechanisms. Angiotensin II increases systemic blood pressure and glomerular capillary pressure, allowing massive proteinuria. In addition, angiotensin II prolongs tubular expression of chemokines and promotes mononucleolar cell infiltration, worsening interstitial pathology. 33, 34 Renal interstitial cells express AT1 receptors, possibly facilitating collagen synthesis and accelerating renal fibrosis. 33 Previous studies have demonstrated that either ARB or ACEI exerts renoprotective actions in diabetic and nondiabetic CKDs.
1- 4 The present results indicated that the patients with angiotensin inhibition were less prone to require dialysis therapy than those without angiotensin inhibition (P ¼ 0.14). The possibility remains that type I error may be present, and the larger scale study would be required. Furthermore, the present findings on non-diabetic CKDs with mild-to-moderate renal dysfunction were compatible with the above, 1 and suggested that while angiotensin inhibition alone might not completely arrest the progression of chronic renal diseases, it gave better chance in improving the renal prognosis as long as both starting dialysis and halved Ccr were considered (Figure 3 ).
The present data indicated that haPWV and baPWV were smaller in angiotensin inhibition group than in the control group in 2006 (Figures 4  and 5 ). These findings are consistent with those of Asmar et al. 35 that perindopril and indapamide were better than atenolol in normalizing arterial function in hypertensives, and have indicated that independent of blood pressure control, angiotensin inhibition attenuated arterial stiffness of not only elastic, but also muscular artery in non-diabetic CKDs. Garg et al. 36 demonstrated that the administration of eprosartan for 8 weeks improved small but not large artery compliance in patients with stage 2-3 nondiabetic CKDs. In harmony, our results indicated that within 1 year angiotensin inhibition group exhibited lower baPWV than control group. We previously reported that in addition to lipid-lowering drugs or vitamin E-coated membrane, angiotensin inhibition was required to improve arterial stiffness in haemodialysis patients. 18 On the one hand, previous data described that ACEI did not decrease cardiovascular events in non-diabetic CKDs. 1 On the other hand, recent studies have demonstrated that either ARB or ACEI decreases cardiovascular events and death in hypertensives.
9,13,37 Banerjee et al. 38 performed retrospective analysis showing that elevated pulse pressure indicated high risk of death or dialysis, and that the benefit of renin-angiotensin system blockade is independent of the baseline pulse pressure in stage 4-5 CKDs including diabetes. Tozawa et al. 39 reported that high pulse pressure predicted cardiovascular complications in Japanese haemodialysis patients from non-diabetic CKDs but not diabetes. The present data on non-diabetic CKDs indicated that angiotensin inhibition improved composite end point of death (Figure 2) . Further larger scale study should be required to draw conclusion on cardiovascular death in itself. Taken together, these results suggest that angiotensin inhibition would keep arterial distensibility and grant organ protection in non-diabetic CKDs.
A caveat should be considered. Firstly, although ARB may not exert completely same actions on blood pressure, Ccr and PWV as ACEI, the data using ARB were combined with those of ACEI because they are statistically indistinguishable in the present study. Secondly, we used PWV as the index of arterial stiffness. 17, 40 All the measurements of PWV were performed after antihypertensive had been prescribed, and after the patient blood pressure had controlled to 130/80 mm Hg to minimize the effects of blood pressure alterations on PWV. Thus, acute changes in vasomotor tone by antihypertensives should have occurred before PWV measurements. Thirdly, although patients without angiotensin inhibition did not show changes in blood pressure for 4 years (Table 2) , there was an increase in arterial stiffness. In control group, systolic pressure and pulse pressure were expected to become higher in 2006 than in 2002, but they were similar. While HR among patients without angiotensin inhibition was 64 bpm in 2002, it tended to increase to 69 bpm in 2006. Faster HR may maintain cardiac output despite possible reductions in stroke volume, accounting for an increase in arterial stiffness without changes in blood pressure. 16 Angiotensin inhibition may offset adverse effects of chronic renal diseases on arterial tree, and may cut off vicious cycle between CKDs and CVDs ( Figure 6 ). Experimental study indicated that renal mass reduction elicited aortic thickening by increasing extracellular matrix and smooth muscle cell proliferation. 41 Arterial stiffness could increase systolic augmentation and central pressure, further worsening glomerular injury without changes in blood pressure measured at brachial artery. 32 Indeed, recent data suggest that arterial stiffness itself is a risk factor in the progression of CKDs. Furthermore, the present study showed a positive correlation between proteinuria and haPWV. The present data that angiotensin inhibition arrested the progressive increment of arterial stiffness in nondiabetic CKDs suggested that angiotensin inhibition protected the kidney via two ways. The one is a well-known intrarenal mechanism to decrease glomerular pressure, and the other is an extrarenal one to decrease central pressure. The latter seems important, because the reduction in arterial stiffness and central pressure should prevent the development of CVD and death in CKDs. [6] [7] [8] 
